EC certificates extended to May 2024

RNS Number : 3756A

Inspiration Healthcare Group PLC

21 January 2020

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Inspiration Healthcare

EC certificates extended to May 2024

As part of Inspiration Healthcare's preparation for the new European Union Medical Device Regulation (MDR) which comes into force in May 2020, the Company confirms that it has now received its new EC Certificate for its products (excluding the recently acquired Viomedex products) to extend until May 2024 their CE marking under the existing Medical Device Directive.

As a result, all Inspiration Healthcare's products will not be adversely affected by the implementation of MDR.  The Company can continue to promote the products where a valid EC Certificate is accepted whilst it applies to its Notified Body (TÜV SÜD) to review its technical documentation under the new regulation.

Commenting today, Neil Campbell, Inspiration Healthcare's Chief Executive said:

"We are pleased to have extended the EC Certificate which allows us to continue to promote the products whilst we review our technical documentation and apply for conformity to the new Medical Device Regulation.  Our new and innovative products in our R&D pipeline are already being developed with MDR in mind and we expect a seamless transition to the MDR in due course."

Enquiries:

Inspiration Healthcare Group plc Neil Campbell, Chief Executive Officer Mike Briant, Chief Financial Officer	Tel: [phone]
Nominated Adviser & Broker Cenkos Securities plc Stephen Keys Mark Connelly Cameron MacRitchie	Tel: [phone]
Cadogan PR                                                                                          Alex Walters [e-mail]	Tel: [phone]

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies. 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products.  This is supported by Technical Support for planned preventative maintenance and emergency assistance.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com

 

END

 

 

NRAFLFLDLRIIFII